Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD−3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Trial Profile

Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD−3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs TD 3504 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 01 Dec 2017 Status changed from recruiting to completed.
    • 19 Jul 2017 Planned End Date changed from 19 Jul 2017 to 31 Aug 2017.
    • 19 Jul 2017 Planned primary completion date changed from 19 Jul 2017 to 31 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top